Elizabeth A Allegretto

US Patent:

55852440, Dec 17, 1996

Filed:

Jun 10, 1994

Appl. No.:

8/258851

Inventors:

Elizabeth A. Allegretto - La Jolla CA
J. Wesley Pike - Encinitas CA

Assignee:

Ligand Pharmaceuticals Incorporated - San Diego CA

International Classification:

G01N 3353
C07K 1618

US Classification:

435 71

Abstract:

The present invention features peptides derived from RXRX, and antibodies elicited by the peptides. These antibodies bind specifically to RXRX subtypes in its native, functional conformation. Methods are disclosed for detection of RXRX with the antibodies in immunological assays. In addition, this invention describes a hormone-binding immunoprecipitation assay which utilizes both the retinoid receptor subtype specific antibodies and retinoid receptor ligands to detect and measure RXR and RAR subtypes in a sample. A method is also disclosed for determining the profile of retinoid receptor subfamily members with the retinoid receptor ligands.

US Patent:

6218430, Apr 17, 2001

Filed:

Aug 24, 1998

Appl. No.:

9/139040

Inventors:

Elizabeth A. Allegretto - La Jolla CA
Marcus F. Boehm - San Diego CA
Alex M. Nadzan - San Diego CA

Assignee:

Ligand Pharmaceuticals Incorporated - San Diego CA

International Classification:

A61K 31336

US Classification:

514475

Abstract:

The present invention relates to non-secosteroidal compounds which activate and modulate the vitamin D receptor (VDR). Because compounds of the present invention display many of the beneficial properties of 1,25(OH). sub. 2 D. sub. 3, but with reduced calcium mobilization effects, they may be used advantageously to treat and prevent conditions that show vitamin D sensitivity. Such disease states typically show abnormal calcium regulatory, abnormal immune responsive, hyperproliferative, and/or neurodegenerative characteristics.